After signing up, you'll start to receive regular news updates from us.
Sequenom Selects Tata Consultancy Services to Develop Framework for Life Science Software Applications
Complete the form below to unlock access to ALL audio articles.
Sequenom Inc. has announced that it has entered into an agreement with Tata Consultancy Services to develop software solutions that will support Sequenom's next generation of software tools and enable the delivery of expanded functionality to their customers.
The software solutions should provide a framework of validated components that will allow Sequenom to develop and deploy software products that will effectively empower its customers to discover, analyze, and report genetic information.
The solutions developed by TCS will include components that provide transparent access to public and private life sciences databases, integration of bioinformatics and computational biology tools within the framework, and enable the design and execution of workflows.
The solutions will also provide for the creation and management of projects for planning user tasks, storing user data and analyses.
TCS' signal processing and life sciences group will develop software modules for improving interfaces to, and signal conditioning of, mass spectrometer data.
Several modules of TCS' software package Bio-Suite™ will be integrated within the framework and will provide analytical capabilities for Sequenom's products.
All development under the agreement will be performed utilizing software development practices and will conform to relevant U.S. Food and Drug Administration (FDA) regulatory standards.
"TCS' experience in developing software solutions for the life sciences, their competencies in bioinformatics, computation techniques, and development process, and an attractive value proposition were important factors in our choice," said Harry Stylli, Ph.D., President and Chief Executive Officer of Sequenom. "We are quite pleased to be working with this world-class organization."
"The software solutions that we are developing will be an important contributor to the success of our efforts to give our customers more value, more rapidly," Dr. Stylli added.
"These software solutions will also be foundational elements for our planned diagnostic initiatives and regulatory compliance efforts."
"The emerging genetics and life sciences sectors present a significant growth opportunity for TCS as it helps us leverage the innovation embedded in this organization," said S. Ramadorai, CEO and MD of TCS.
"TCS is investing in developing new competencies in emerging sectors through its R&D labs as well as through research collaborations with leading universities across the world," Mr. Ramadorai added.
"This engagement which uses Bio-Suite components is further proof of TCS' ability to successfully translate R&D into go-to-market solutions."
Dr. M. Vidyasagar, Executive Vice President and Head, Advanced Technology Centre, TCS Hyderabad, which houses the Life Sciences R&D Division, said, "With personalized and targeted medicines becoming important medical tools, working with Sequenom, TCS will develop computational tools that will assist in addressing these requirements."
"We are committed to creating a complete suite of offerings for life sciences, spanning genomics, proteomics, database integration, drug discovery and preventive healthcare and this is an important milestone in that effort."
